ESMO 2019: PARP inhibitor maintenance in ovarian cancer prolongs PFS in first line patients
Three new studies have shown that recurrence of ovarian cancer can be delayed by giving PARP inhibitors after chemotherapy. These results build on the success of the SOLO1 trial last year, and make a compelling case for treatment. Improvements in life expectancy remain elusive for the time being.